March 4, 2015
Santen Pharmaceutical announced on March 2 that the European Medicines Agency has accepted a marketing authorization application (MAA) for its investigational agent DE-109 (intravitreal sirolimus), an mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment of...read more